Literature DB >> 10359664

Phosphorylation of the myristoylated protein kinase C substrate MARCKS by the cyclin E-cyclin-dependent kinase 2 complex in vitro.

S Manenti1, E Yamauchi, O Sorokine, M Knibiehler, A Van Dorsselaer, H Taniguchi, B Ducommun, J M Darbon.   

Abstract

The myristoylated alanine-rich C-kinase substrate (MARCKS) purified from brain was recently characterized as a proline-directed kinase(s) substrate in vivo [Taniguchi, Manenti, Suzuki and Titani (1994) J. Biol. Chem. 269, 18299-18302]. Here we have investigated the phosphorylation of MARCKS by various cyclin-dependent kinases (Cdks) in vitro. We established that Cdk2, Cdk4 and, to a smaller extent, Cdk1 that have been immunoprecipitated from cellular extracts phosphorylate MARCKS. Comparison of MARCKS phosphorylation by protein kinase C (PKC) and by the purified cyclin E-Cdk2 complex suggested that two residues were phosphorylated by Cdk2 under these conditions. To identify these sites, Cdk2-phosphorylated MARCKS was digested with lysyl endoprotease and analysed by electrospray MS. Comparison with the digests obtained from the unphosphorylated protein demonstrated that two peptides, Gly12-Lys30 and Ala138-Lys152, were phosphorylated by cyclin E-Cdk2. The identity of these peptides was confirmed by automatic Edman degradation. On the basis of the consensus phosphorylation sequence described for Cdk2, and on MS/MS analysis of the Ala138-Lys152 peptide, we concluded that Ser27, one of the phosphorylation sites identified in vivo, and Thr150 were the Cdk2 targets in vitro. None of the other sites described in vivo were phosphorylated in these conditions. Interestingly, a preliminary phosphorylation of MARCKS by PKC improved the initial rate of phosphorylation by Cdk2 without modifying the number of sites concerned. In contrast, phosphorylation of MARCKS by Cdk2 did not significantly affect further phosphorylation by PKC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359664      PMCID: PMC1220311     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

Review 1.  The MARCKS brothers: a family of protein kinase C substrates.

Authors:  A Aderem
Journal:  Cell       Date:  1992-11-27       Impact factor: 41.582

2.  The C-terminal conserved domain of MARCKS is phosphorylated in vivo by proline-directed protein kinase. Application of ion trap mass spectrometry to the determination of protein phosphorylation sites.

Authors:  E Yamauchi; R Kiyonami; M Kanai; H Taniguchi
Journal:  J Biol Chem       Date:  1998-02-20       Impact factor: 5.157

3.  Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes.

Authors:  F Mouriaux; F Casagrande; M J Pillaire; S Manenti; F Malecaze; J M Darbon
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-05       Impact factor: 4.799

4.  Cyclin E-CDK2 is a regulator of p27Kip1.

Authors:  R J Sheaff; M Groudine; M Gordon; J M Roberts; B E Clurman
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Phosphorylation-dependent binding of a synthetic MARCKS peptide to calmodulin.

Authors:  B K McIlroy; J D Walters; P J Blackshear; J D Johnson
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

7.  Molecular determinants of the myristoyl-electrostatic switch of MARCKS.

Authors:  J T Seykora; M M Myat; L A Allen; J V Ravetch; A Aderem
Journal:  J Biol Chem       Date:  1996-08-02       Impact factor: 5.157

8.  Phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) by proline-directed protein kinases and its dephosphorylation.

Authors:  H Yamamoto; F Arakane; T Ono; K Tashima; E Okumura; K Yamada; S Hisanaga; K Fukunaga; T Kishimoto; E Miyamoto
Journal:  J Neurochem       Date:  1995-08       Impact factor: 5.372

9.  A mass spectrometric study on the in vivo posttranslational modification of GAP-43.

Authors:  H Taniguchi; M Suzuki; S Manenti; K Titani
Journal:  J Biol Chem       Date:  1994-09-09       Impact factor: 5.157

10.  Protein kinase C regulates MARCKS cycling between the plasma membrane and lysosomes in fibroblasts.

Authors:  L A Allen; A Aderem
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

View more
  7 in total

Review 1.  Cross-talk unfolded: MARCKS proteins.

Authors:  Anna Arbuzova; Arndt A P Schmitz; Guy Vergères
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

2.  CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

Authors:  Stacey J Baker; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2012-11

Review 3.  Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.

Authors:  Richard S Finn; Alexey Aleshin; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2016-02-09       Impact factor: 6.466

Review 4.  CDK4: a master regulator of the cell cycle and its role in cancer.

Authors:  Stacey J Baker; Poulikos I Poulikakos; Hanna Y Irie; Samir Parekh; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2022-08-25

5.  Identification of CDK2 substrates in human cell lysates.

Authors:  Yong Chi; Markus Welcker; Asli A Hizli; Jeffrey J Posakony; Ruedi Aebersold; Bruce E Clurman
Journal:  Genome Biol       Date:  2008-10-13       Impact factor: 13.583

6.  A novel effect of MARCKS phosphorylation by activated PKC: the dephosphorylation of its serine 25 in chick neuroblasts.

Authors:  Andrea Toledo; Flavio R Zolessi; Cristina Arruti
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

7.  Searching for novel Cdk5 substrates in brain by comparative phosphoproteomics of wild type and Cdk5-/- mice.

Authors:  Erick Contreras-Vallejos; Elías Utreras; Daniel A Bórquez; Michaela Prochazkova; Anita Terse; Howard Jaffe; Andrea Toledo; Cristina Arruti; Harish C Pant; Ashok B Kulkarni; Christian González-Billault
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.